Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Signals of Gut Microbiome Interaction With Experimental Alzheimer’s Drug Prompt New Trial

Publish date:: September 10, 2019

Key clinical point: An investigational Alzheimer’s drug appears to interact with the gut microbiome.

Major finding: Levels of “good,” butyrate-producing bacteria were higher in patients who responded well to Anavex 2-73. A bacterial family important in gut homeostasis, however, was decreased in those who responded poorly.

Study details: The stool sampling was conducted in 16 patients.

Disclosures: Dr. Missling is the president of Anavex Life Sciences.

Citation:

Missling C et al. AAIC 2019, Abstract 32260.

This Week's Must Reads

MDD: Modest improvements in female sexual functioning with adjunctive brexpiprazole,

Transcranial direct current stimulation not clinically relevant in MDD,

Interleukin-1 β and TNF-α hamper antidepressant response in MDD,

Impact of pimavanserin on anxious depression in patients with MDD,

Prior MDD moderates the association between endothelin-1 and post-ACS depressive symptoms,

Must Reads in Alzheimer's & Cognition

Vascular dementia risk particularly high in type 2 diabetes,

Mortality burden of dementia may be greater than estimated,

Cognitive deficits complex in youths with type 2 diabetes,

Population study supports migraine-dementia link,

Mixed results for aducanumab in two phase 3 trials for Alzheimer’s disease,